Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

• Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation of triterpenoid antifungals (fungerps).
• Next-generation fungerps, in preclinical stages of development, are targeted to have enhanced pharmacological properties to treat fungal infections where current therapies are limited or not effective, while maintaining broad spectrum of activity against resistant fungal pathogens.

 
JERSEY CITY, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that a novel series of antifungal compounds utilizing SCYNEXIS’ proprietary triterpenoid antifungal platform are among the five projects funded by the federal grant awarded to the new accelerator consortium led by researchers from Hackensack Meridian Center for Discovery and Innovation (CDI) and the Johns Hopkins Bloomberg School of Public Health. A five-year federal grant will establish a Center of Excellence in Translational Research (CETR) jointly between researchers from the Bloomberg School and the CDI, and other academic and commercial collaborators. The CETR expects to receive about $7 million annually, contingent upon the availability of funds, with the support coming from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID).

“With approximately four million annual deaths attributable to fungal infections globally¹, this new grant from the NIH provides essential funding to support the development of new therapeutics that can address the growing threat from resistant fungal infections,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. “As part of this research collaboration, we are pleased to note that a series of next-generation fungerp candidates are included, with the aim to progress their development from early preclinical stage to IND ready candidates. For this collaboration we have selected a few fungerps with key attributes including activity against resistant fungi and differentiated pharmacological properties, critical for addressing significant limitations of currently available antifungal armamentarium. We are very pleased to collaborate with this CETR in tackling one of the world’s most pressing health threats.”